acalabrutinib
Ligand Summary
Acalabrutinib is a small-molecule inhibitor of BTK. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, an adhesion. In nonclinical studies, acalabrutinib inhibited BTK mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and survival.
UNII: I42748ELQW
PubChem: 71226662
Guide to Pharmacology: 8912
ChEMBL: CHEMBL3707348
DrugCentral: 5260
LyCHI: XXKFJ6FZGLB5
Target Activities
29 Activities
Items per page:
1 – 10 of 29
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
EC50 | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
EC50 | ||||||
IC50 | ||||||
IC50 | ||||||